A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Compared to a Standard Nine-Month Regimen for Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Isoniazid, Rifampicin, and Linezolid Antimicrobial Agents for TBM (IMAGINE-TBM).

 

Main Inclusion Criteria:

1. Probable or presumed diagnosis of meningitis due to Mycobacterium tuberculosis

2. 15 years of age or older

3. Not having used TB medication for more than 14 days prior to study entry (e.g., INH, RIF, LZD, PZA)

4. Not having used MTB medication 90 days prior to study entry

5. Not having had a current or previous infection with drug-resistant MTB

6. Not having another etiology of meningitis (Cryptococcus, etc.)

​

Status: Study recruiting.